Ascendis Pharma A (ASND) EBITDA Margin Growth (3y) (2017 - 2026)
Powered by 
Analysis
Ascendis Pharma A (ASND) EBITDA Margin Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -377.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -204.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 7,045.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1,934.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 7,261.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 9,003.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -2,649.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 30,461.00 |
| 10 | Ascendis Pharma A | 16.39 Bn | 15.45 Bn | 362.22 Mn | 36,215.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 36,215.00 |
| Mar 31, 2026 | 43,841.00 |
| Dec 31, 2025 | 57,372.00 |
| Sep 30, 2025 | 95,024.00 |
| Jun 30, 2025 | 226,995.00 |
| Mar 31, 2025 | 177,376.00 |
| Dec 31, 2024 | 11,641.00 |
| Sep 30, 2024 | 854,179.00 |
| Jun 30, 2024 | 1.11 Mn |
| Mar 31, 2024 | 1.67 Mn |
| Dec 31, 2023 | 11,490.00 |
| Sep 30, 2023 | 257,927.00 |
| Jun 30, 2023 | 547,908.00 |
| Mar 31, 2023 | 286,234.00 |
| Dec 31, 2022 | -40,693.00 |
| Sep 30, 2022 | 146,306.00 |
| Jun 30, 2022 | -69,726.00 |
| Mar 31, 2022 | -83,551.00 |
| Dec 31, 2021 | 2,507.00 |
| Sep 30, 2021 | 18.27 Mn |